Title of article :
Early outpatient administration of Remdesivir shortens recovery time in patients with mild to moderate COVID-19
Author/Authors :
Hajimaghsoudi ، Majid Department of Emergency Medicine - Faculty of Medicine - Shahid Sadoughi University of Medical Sciences , Saghafi ، Fatemeh Department of Clinical Pharmacy - Faculty of Pharmacy and Pharmaceutical Sciences - Shahid Sadoughi University of Medical Sciences , Shorabi ، Mahya Student Research Committee, Faculty of Paramedicine - Shahid Sadoughi University of Medical Sciences and Health Services , Mirzaei ، Samaneh Department of Health in Emergencies and Disasters - School of Public Health - Shahid Sadoughi University of Medical Sciences and Health Services , Moharami ، Mehrnaz Student Research Committee, Faculty of Paramedicine - Shahid Sadoughi University of Medical Sciences and Health Services , Daryaei ، Negin Student Research Committee, Faculty of Paramedicine - Shahid Sadoughi University of Medical Sciences and Health Services , Hoseinzade ، Farahnaz Department of Clinical Pharmacy and Pharmacy Practice - School of Pharmacy and Pharmaceutical Sciences - Isfahan University of Medical Sciences , Jalili ، Farzad Student Research Committee, Faculty of Medicine - Shahid Sadoughi University of Medical Sciences and Health Services , Rezaei ، Hamid Reza Student Research Committee, Faculty of Medicine - Shahid Sadoughi University of Medical Sciences and Health Services , Rameshi ، Yekta Pharmaceutical Sciences Research Center, Student Research Committee, School of Pharmacy - Shahid Sadoughi University of Medical Sciences and Health Services , Gholinataj Jelodar ، Mohsen Department of Internal Medicine - Faculty of Medicine - Shahid Sadoughi University of Medical Sciences
Abstract :
Background: During COVID-19, healthcare systems in underdeveloped nations had significant challenges and were unlikely to offer the necessary care. It appears that a new, reliable healthcare model that prevents hospitalization is necessary to reduce the pressure that COVID-19 is putting on healthcare systems and patients. More particularly, as Remdesivir s use as an outpatient treatment for mild to severe SARS-CoV-2 infection has rarely been examined; we aimed to investigate in-depth comprehension of the effects of Remdesivir in these cases. Methods: In our two-month cross-sectional study, non-hospitalized patients with mild to moderate COVID-19 who were referred to the hospital for up to 5 days of Remdesivir treatment received 200 mg of Remdesivir intravenously on day 1, followed by 100 mg of Remdesivir once daily for the subsequent 4 days. Patients were divided into groups based on the time of starting Remdesivir treatment after the appearance of symptoms: group 1 less than and equal to 7 days, and group 2 more than 7 days. Two groups were evaluated for a correlation between Remdesivir administration time and clinical symptoms on days 1 and 14 (follow-up visits). Results: The study enrolled 273 eligible patients with a mean age of 47.5 years, of whom 112 were males and 125 were females. Results showed that patients who received Remdesivir in the first 7 days had less dyspnea (P-value lt;0.0001) and lung involvement (P-value lt;0.0001) than those who received it after 7 days at the end of the study. Patients who came later to receive Remdesivir also showed higher fatigue, AST, and ALT levels on the first day. Conclusions: Among patients with moderate COVID-19, those who received a 5-day course of Remdesivir within 7 days of the onset of symptoms had a statistically significant difference in clinical status compared with those who received their treatments later. However, the size of this finding has uncertain clinical importance.
Keywords :
COVID , 19 , SARS , CoV , 2 , Outpatient , Remdesivir, Complications
Journal title :
Journal of Pharmaceutical Care
Journal title :
Journal of Pharmaceutical Care
